Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830258 | 0.99 | GSK3B (0.49) | GSK3BGRM5CYP2D6 | |
| SCHEMBL1831168 | 0.82 | ALDH1A1 (0.51) | GSK3BGRM5MEN1KMT2AHDAC6 | |
| SCHEMBL927260 | 0.82 | GSK3B (0.47) | GSK3BCYP2D6 | |
| SCHEMBL3568709 | 0.76 | GSK3B (0.48) | GSK3BALDH1A1POLB | |
| SCHEMBL1834667 | 0.76 | GSK3B (0.51) | GSK3BCYP2D6 | |
| SCHEMBL2065123 | 0.75 | GSK3B (0.47) | GSK3BCYP2D6 | |
| SCHEMBL1832336 | 0.75 | GSK3B (0.47) | GSK3BCYP2D6 | |
| SCHEMBL1833143 | 0.74 | GSK3B (0.46) | GSK3BCYP2D6 | |
| SCHEMBL1834981 | 0.74 | GSK3B (0.46) | GSK3BCYP2D6 | |
| SCHEMBL915365 | 0.74 | GSK3B (0.46) | GSK3BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321315-B1 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-06-03 | — | — | EP | disclosed |
| EP-2321316-B1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-8614219-B2 | Substituted pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2013-12-24 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144092-A1 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2321316-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-2321315-A2 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-2138494-A1 | Substituted alkyl pyrimidin-4-one derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138492-A1 | Substituted pyrimidin-4-one derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156864-A2 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156865-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GRM5 1114/4885MEN1 3328/4885 |
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | TYMP, DHFR, DPYD | GSK3B 3574/4885GRM5 3230/4885MEN1 1510/4885 |
| US-20110144092-A1 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES | DPYD, TYMP, DHFR | GSK3B 3837/4885GRM5 2682/4885MEN1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.